Fangyu Yang1, Qianyi Huang1, Zhongying Guan2, Qizhi Diao3. 1. Clinical Laboratory Medicine of Yongchuan Hospital, Chongqing Medical University, No. 439, Xuanhua Road, Yongchuan District, Chongqing, 402160, China. 2. Clinical Laboratory Medicine of Affiliated Hospital 2, Liaoning University Traditional Chinese Medicine, Liaoning, China. 3. Clinical Laboratory Medicine of Yongchuan Hospital, Chongqing Medical University, No. 439, Xuanhua Road, Yongchuan District, Chongqing, 402160, China. diaoqizhi@163.com.
Abstract
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with the progression of laryngeal cancer (LC), but studies have reported inconsistent results. We systematically evaluated the effect of the pretreatment NLR on the prognosis of LC in the meta-analysis. METHOD: The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched from January 1, 2000 to September 10, 2019, to identify studies investigating the relationship between the NLR and outcomes in LC patients. The fixed-effects model was used to assess the pooled hazard ratio (HR), along with the 95% confidence interval (95% CI). RESULTS: A total of 105 records were obtained through the databases and 12 studies enrolling 3710 patients were included in the meta-analysis. The pooled overall survival (OS, HR = 1.76, 95% CI 1.53-2.03, P < 0.001), progression-free survival (PFS, HR = 1.72, 95% CI 1.38-2.13, P < 0.001) and disease-free survival (DFS, HR = 1.66, 95% CI 1.33-2.07, P < 0.001) indicated that a higher NLR led to a poorer prognosis for patients with LC. In terms of publication year, country, cutoff value, cutoff method, treatment modality, statistical model and NOS score, subgroup analyses consistently showed a worse OS in patients with an elevated NLR. Additionally, there was no significant difference among the subgroups (all P for heterogeneity > 0.05). CONCLUSION: An elevated pretreatment NLR is significantly associated with poorer prognosis in patients with LC. NLR values are easily obtained from routinely collected blood samples and could assist clinicians in determining the prognosis of LC patients.
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with the progression of laryngeal cancer (LC), but studies have reported inconsistent results. We systematically evaluated the effect of the pretreatment NLR on the prognosis of LC in the meta-analysis. METHOD: The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched from January 1, 2000 to September 10, 2019, to identify studies investigating the relationship between the NLR and outcomes in LC patients. The fixed-effects model was used to assess the pooled hazard ratio (HR), along with the 95% confidence interval (95% CI). RESULTS: A total of 105 records were obtained through the databases and 12 studies enrolling 3710 patients were included in the meta-analysis. The pooled overall survival (OS, HR = 1.76, 95% CI 1.53-2.03, P < 0.001), progression-free survival (PFS, HR = 1.72, 95% CI 1.38-2.13, P < 0.001) and disease-free survival (DFS, HR = 1.66, 95% CI 1.33-2.07, P < 0.001) indicated that a higher NLR led to a poorer prognosis for patients with LC. In terms of publication year, country, cutoff value, cutoff method, treatment modality, statistical model and NOS score, subgroup analyses consistently showed a worse OS in patients with an elevated NLR. Additionally, there was no significant difference among the subgroups (all P for heterogeneity > 0.05). CONCLUSION: An elevated pretreatment NLR is significantly associated with poorer prognosis in patients with LC. NLR values are easily obtained from routinely collected blood samples and could assist clinicians in determining the prognosis of LC patients.
Authors: Conor E Steuer; Mark El-Deiry; Jason R Parks; Kristin A Higgins; Nabil F Saba Journal: CA Cancer J Clin Date: 2016-11-29 Impact factor: 508.702
Authors: Cathy Ndiaye; Marisa Mena; Laia Alemany; Marc Arbyn; Xavier Castellsagué; Louise Laporte; F Xavier Bosch; Silvia de Sanjosé; Helen Trottier Journal: Lancet Oncol Date: 2014-10-16 Impact factor: 41.316
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Robert P Takes; Alessandra Rinaldo; Carl E Silver; Jay F Piccirillo; Missak Haigentz; Carlos Suárez; Vincent Van der Poorten; Robert Hermans; Juan Pablo Rodrigo; Kenneth O Devaney; Alfio Ferlito Journal: Head Neck Date: 2010-12 Impact factor: 3.147
Authors: Neal D Freedman; Christian C Abnet; Michael F Leitzmann; Albert R Hollenbeck; Arthur Schatzkin Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Denise H E Maasland; Piet A van den Brandt; Bernd Kremer; R Alexandra Sandra Goldbohm; Leo J Schouten Journal: BMC Cancer Date: 2014-03-14 Impact factor: 4.430